Arrowhead Pharmaceutical

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using abroad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Pipeline Development Strategy

Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics.

Leadership

Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products.